Pharmacists Improving Treatment Adherence & Patient Outcomes in Atopic Dermatitis (AD)
A free online accredited CPD program for Canadian Pharmacists
Up to 17% of Canadians will develop AD during their lifetime.
Up to 17% of Canadians will develop AD during their lifetime. AD or eczema can occur at any age but usually appears in early childhood with the possibility of disease flares occurring throughout a patient’s adulthood.
AD affects both the patient and their family with its ongoing itch-scratch cycle that compromises sleep and negatively affects quality of life.
AD treatment focuses on the immediate need of treating an acute flare’s itch and inflammation with the long-term goal of promoting maintenance of the skin barrier. The treatment approach includes prescribed topical treatment, proper skin hydration and a long-term skin care program.
Program Planning Committee
Adam Natsheh, MD, FRCPC (Derm), BSc (Pharm)
Ron Pohar, BScPharm, APA
Brad Couldwell, BScPharm., APA, CDE, CTH
1 CEU CCCEP & 1 CEU OPQ
Program available online until: September 19, 2017
Course Learning Objectives
- Identify the key aspects of diagnosing and treating eczema, specifically atopic dermatitis (AD).
- Describe the safe and appropriate use of various treatment options, including the important role of topical calcineurin inhibitors (TCI) in achieving and maintaining control of eczema.
- Improve treatment adherence and patient outcomes in eczema through effective counselling, patient education, and by utilizing the pharmacist scope of practice.
Questions answered by our expert: David Adam, MD, FRCPC
- What are the recommendations for treating AD flares?
- What are the major adherence issues when using topical corticosteroids (TCs) or topical calcineurin inhibitors (TCIs)?
- What are the important differences between use of topical corticosteroids (TCs) and topical calcineurin inhibitors (TCIs)?
- What is the best approach for the maintenance of AD therapy?